Compare with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES GSK PHARMA ALKEM LABORATORIES/
GSK PHARMA
 
P/E (TTM) x 22.4 53.4 42.0% View Chart
P/BV x 5.4 12.0 44.9% View Chart
Dividend Yield % 0.9 1.3 68.2%  

Financials

 ALKEM LABORATORIES   GSK PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
GSK PHARMA
Mar-19
ALKEM LABORATORIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7203,595 75.7%   
Low Rs1,6601,253 132.5%   
Sales per share (Unadj.) Rs697.9184.7 377.9%  
Earnings per share (Unadj.) Rs96.126.3 365.6%  
Cash flow per share (Unadj.) Rs117.329.2 402.1%  
Dividends per share (Unadj.) Rs25.0020.00 125.0%  
Dividend yield (eoy) %1.10.8 138.3%  
Book value per share (Unadj.) Rs515.2126.3 407.9%  
Shares outstanding (eoy) m119.57169.40 70.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.113.1 23.9%   
Avg P/E ratio x22.892.2 24.7%  
P/CF ratio (eoy) x18.783.1 22.5%  
Price / Book Value ratio x4.319.2 22.2%  
Dividend payout %26.076.1 34.2%   
Avg Mkt Cap Rs m261,879410,626 63.8%   
No. of employees `00014.35.0 288.9%   
Total wages/salary Rs m15,0555,372 280.2%   
Avg. sales/employee Rs Th5,822.66,306.7 92.3%   
Avg. wages/employee Rs Th1,050.51,083.1 97.0%   
Avg. net profit/employee Rs Th802.0898.0 89.3%   
INCOME DATA
Net Sales Rs m83,44431,281 266.8%  
Other income Rs m1,0421,023 101.9%   
Total revenues Rs m84,48632,304 261.5%   
Gross profit Rs m14,7346,009 245.2%  
Depreciation Rs m2,528486 520.1%   
Interest Rs m6516 10,843.3%   
Profit before tax Rs m12,5986,540 192.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m1,1052,373 46.6%   
Profit after tax Rs m11,4934,454 258.0%  
Gross profit margin %17.719.2 91.9%  
Effective tax rate %8.836.3 24.2%   
Net profit margin %13.814.2 96.7%  
BALANCE SHEET DATA
Current assets Rs m54,96020,061 274.0%   
Current liabilities Rs m32,43314,543 223.0%   
Net working cap to sales %27.017.6 153.0%  
Current ratio x1.71.4 122.8%  
Inventory Days Days8057 140.2%  
Debtors Days Days7214 513.1%  
Net fixed assets Rs m32,71014,343 228.1%   
Share capital Rs m2391,694 14.1%   
"Free" reserves Rs m61,36819,704 311.4%   
Net worth Rs m61,60721,398 287.9%   
Long term debt Rs m1,5922 79,620.0%   
Total assets Rs m99,43339,113 254.2%  
Interest coverage x20.41,091.0 1.9%   
Debt to equity ratio x00 27,655.0%  
Sales to assets ratio x0.80.8 104.9%   
Return on assets %12.211.4 107.1%  
Return on equity %18.720.8 89.6%  
Return on capital %21.031.9 65.7%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,061534 3,007.7%   
Fx outflow Rs m2,4837,091 35.0%   
Net fx Rs m13,578-6,557 -207.1%   
CASH FLOW
From Operations Rs m5,8513,994 146.5%  
From Investments Rs m-7,414-1,433 517.2%  
From Financial Activity Rs m792-3,584 -22.1%  
Net Cashflow Rs m-731-1,023 71.5%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 33.1 10.2 324.5%  
FIIs % 0.0 23.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 15.4 -  
Shareholders   68,381 102,036 67.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat, GAIL and UPL Among Top Nifty Gainers(Closing)

Indian share markets continued their volatile trend during closing hours today and ended their day on a flat note.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 8, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS